Today, in Healthtech, we are held back by the comfort of a “familiar uncertainty” for which we have done little to challenge in the past. Many players in silico medicine have questioned this status quo. Some have demonstrated that through computational modeling and simulation support, an initial set of evidence generated by a few hundred patients instead of 1000 could be sufficient for approval by regulators, potentially saving millions in drug and medical device development costs and reducing the time to market by years. To make this happen, the alignment of data generators, product developers, and regulators is essential.
Relive the event
Last events
Event
Afterwork: Key Takeaways from JP Morgan’s Annual Healthcare Conference 2024 in Neighborhood
After two years of turmoil, tough financing, pipeline slimming and cost-cutting… prospects finally look brighter for the…
Event
The Neighborhood Showcase 2023 in Neighborhood
After a year of hard work on producing their development plans and regulatory strategy, Neighborhood’s Start-up Class of 2023 will…
Event
Afterwork: AI a revolution for Healthtech development and Investment? in Neighborhood
AI and in silico models are set to revolutionize biotech investments and transform the entire health innovation ecosystem, join us…
Event
Afterwork: Seen & Heard, Last Week, at JP Morgan’s Annual Healthcare Conference 2023 in Neighborhood
Rising interest rates have triggered a fall in market valuation, and an indirect brutal loss in appetite from VC and…
We'd love to get to know you
Join us, we offer you an extraordinary chance to learn, to develop and to be part of an exciting experience and team.
Tell us your story